Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC)
Oh, D. Y. He, A. R. Qin, S. Chen, L. T. Okusaka, T. Vogel, A. Kim, J. W. Suksombooncharoen, T. Lee, M. A. Kitano, M.
Oh, D. Y.
He, A. R.
Qin, S.
Chen, L. T.
Okusaka, T.
Vogel, A.
Kim, J. W.
Suksombooncharoen, T.
Lee, M. A.
Kitano, M.
Citations
Altmetric:
Abstract
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Oh DY, He AR, Qin S, Chen LT, Okusaka T, Vogel A, et al. Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC). Annals of Oncology. 2022 Sep;33(7):S565-S6. PubMed PMID: WOS:000866211600056.